R&D channel feed – Endpoints News

R&D channel feed

Biogen scores a priority review for its Alzheimer's drug aducanumab, moving one giant leap forward in its controversial quest

5 years ago

In surprising setback, combo of Roche’s Tecentriq and chemo fails to help patients with triple-negative breast cancer

5 years ago

AbbVie abandons a pioneering CRISPR R&D alliance with Editas as Brent Saunders' deal is cast out

5 years ago

Levo Therapeutics misses primary endpoint in PhIII trial of Prader-Willi drug — the latest setback in a disaster-prone field

5 years ago

Regeneron adds more positive PhIII data for its NGF program — but safety is still a big concern

5 years ago

Pfizer's Lorbrena bests Xalkori in PhIII readout — is it a potential successor?

5 years ago

Roche-backed Dicerna pushes into the pack racing toward the blockbuster hep B goal line, armed with PhI data

5 years ago

FDA approves GSK's BCMA drug, marking a rocky return to cancer for the British giant

5 years ago

Lundbeck sounds taps on another CNS drug, retreating from a mine field still occupied by a Merck team

5 years ago

Novartis says Kymriah reaches primary endpoint in new PhII, although numbers still to come

5 years ago

AbbVie shrugs off $134M cash deals, quitting a neuro R&D pact with Voyager Therapeutics on vectorized antibody treatments

5 years ago

Merck scoops up a PhII J&J discard in a bargain-basement deal. And this time they’re shooting at NASH

5 years ago

AstraZeneca throws Redx a lifeline — in exchange for a preclinical fibrosis drug — with a promise of $17M in quick cash plus milestones

5 years ago

When will it end? Goldman economist gives late-stage vaccines a good shot at targeting 'large shares' of the US by mid-2021 — but the downside is daunting

5 years ago

J&J gets a fresh OK for esketamine, but is it really the game-changer for depression Trump keeps tweeting about?

5 years ago

CymaBay flashes positive results from the trial they have to relaunch

5 years ago

Immunic's lead MS drug hits primary and key secondary endpoints in PhII, but questions remain

5 years ago

FDA hands MorphoSys and Incyte a quick OK on their potential blockbuster CAR-T alternative

5 years ago

So Covid-19 leader BioNTech has a cancer vaccine in development? Yes, and Regeneron just jumped in for the PhII combo study

5 years ago

Roche snags an FDA approval for an advanced melanoma drug cocktail — but it's up against some fierce competition

5 years ago

Lexicon bids farewell to top seller Xermelo in reorganization toward R&D pipeline

5 years ago

The lead drug in Alexion’s $930M buyout deal last fall just flopped — adding injury to analysts’ M&A insults

5 years ago

Covid-19 afflicts Eli Lilly’s share price and a KRAS drug gets tossed, but Jardiance win salves the wound as an antibody effort advances to PhII

5 years ago

AbbVie preps a challenge to a rival migraine drug from Biohaven, spelling out an upbeat set of PhIII data

5 years ago

First page Previous page 193 194 195196197 198 199 Next page Last page